



ABN 82 010 975 612

Level 18, 101 Collins Street  
Melbourne, Victoria 3000 Australia  
Telephone: + 61 7 3088 7926  
Facsimile: + 61 7 3394 4394

### **Update of Principal Place of Business Address**

**Melbourne, Australia, 13 October 2016.** TBG Diagnostics Limited (ASX: TDL, OTC: PGLA) (the **Company** or **TBG**) wishes to advise that its principal place of business address details have changed with immediate effect to:

Level 18, 101 Collins Street  
Melbourne  
VIC 3000  
Australia  
Tel No: 07 3088 7926  
Fax No: 07 3394 4394

Please note that the Company's telephone and fax numbers have also changed.

#### **For more information:**

Blair Lucas  
Company Secretary  
+61 7 3088 7926  
+61 403 358 638

#### **About TBG Diagnostics**

TBG Diagnostics is a global molecular diagnostic (MDx) company operating in the IVD (in vitro diagnostics) industry. TBG is focused on the development, manufacture and marketing of molecular diagnostic kits, instruments and services

TBG Diagnostics is an established brand with a strong presence in the Asian market. From its plant in Xiamen, China it develops and manufactures:

- Nucleic Acid Test (NAT) products
- HLA typing reagents based on NAT technologies
- Automation systems for NAT operations
- IVD-related NAT kits and services

Products distributed to more than 22 countries. Major hospital and laboratory clients in USA, Taiwan, Germany, Portugal, China, Hong Kong and Singapore. Operating in the rapidly growing IVD market - US\$53 billion in 2013 and expected to reach US\$74.7 billion by 2020 (This is huge to say we operate in the IVD market. More realistically, we operate in the MDx market which is growing from 10% (\$6Bn USD) to 25.2% (\$25Bn USD) of total IVD market share by 2024.)

Targeting further growth in China - fastest growing MDx market at CAGR of 27.9%. Extensive research and development pipeline targeting products for oncology, infectious diseases, transplants, transfusions, pharmacogenetics, autoimmune diseases and genetic diseases